1 / 31

La ricerca nello scompenso cardiaco acuto: ci sono reali novità?

La ricerca nello scompenso cardiaco acuto: ci sono reali novità?. Aldo P Maggioni Centro Studi ANMCO Firenze. L’epidemiologia dello scompenso acuto rimane un problema rilevante senza segni di miglioramento nel tempo. AHF vs CHF outcomes. Lee DS, Am. J. Med. 2004.

Sophia
Download Presentation

La ricerca nello scompenso cardiaco acuto: ci sono reali novità?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. La ricerca nello scompenso cardiaco acuto: ci sono reali novità? Aldo P Maggioni Centro Studi ANMCO Firenze

  2. L’epidemiologia dello scompenso acuto rimane un problema rilevante senza segni di miglioramento nel tempo

  3. AHF vs CHF outcomes Lee DS, Am. J. Med. 2004

  4. La ricerca sui trattamenti dello scompenso cardiaco acuto • Fallimenti • Semidelusioni • Piccoli successi

  5. 1990 ‘91 ‘92 ‘93 ‘94 ‘95 ‘96 ‘97 1998 Flosequinon Sopravvivenza dei farmaci per lo S.C. grave Xamoterolo Milrinone (PROMISE) Vesnarinone (VEST) Ibopamina (PRIME-2) Pimobendan Epoprostenol (First) Bosentan (REACH-1)

  6. La ricerca sui trattamenti dello scompenso cardiaco acuto • Fallimenti • Semidelusioni

  7. A. Mebazaa et al., JAMA 2007, 297: 1883-1891

  8. BNP A. Mebazaa et al., JAMA 2007, 297: 1883-1891 A. Mebazaa et al., JAMA 2007, 297: 1883-1891

  9. A. Mebazaa et al., JAMA 2007, 297: 1883-1891 A. Mebazaa et al., JAMA 2007, 297: 1883-1891

  10. La ricerca sui trattamenti dello scompenso cardiaco acuto • Fallimenti • Semidelusioni • Piccolisuccessi

  11. M.A. Konstam et al., JAMA 2007, 297: 1319-1331

  12. M.A. Konstam et al., JAMA 2007, 297: 1319-1331

  13. Per cominciare a ragionare più seriamente • E’ possibile fare una stratificazione dei rischi affidabile ?

  14. EHS HF II: data collection • Patients screened at the emergency area, including cardiac care unit (CCU) or intensive care unit (ICU), as well as on ward facilities (internal medicine or cardiology) • 133 participating hospitals: • university hospitals (47%) • community or district hospitals (49%) • private clinics (4%) • 30 European countries • Recruitment from 21 October 2004 until 31 August 2005

  15. EHFS II: All-Cause in-Hospital Mortality 39.6% 6.6% 5.3% 5.4% n. 3580 pts n. 139 pts n. 2202 pts n. 1239 pts

  16. Univariate analysis: in-hospital mortality by age, SBP and creatinine at hospital entry 12.9% (n. 3441 patients) 10.8% 9.3% 6.4% 5.7% 5.1% 3.4% 3.4% 3.0% <65 65-80 >80 >130 110-130 <110 <1.4 1.4-2.0 >2.0

  17. EHFS II: All-cause in-hospitalmortality bystrataofrisk score Risk score 743 772 726 574 305 321 N. ofpts

  18. Per cominciare a ragionarepiùseriamente • E’ possibile fare unastratificazionedeirischiaffidabile ? • Quali end-point e a quali tempi dobbiamomisurarli ?

  19. All-causemortality: The lessonslearnedfromtrials and registries... Chronic HF ACS Acute HF Opasich C et al. for the IN-CHF Investigators. Am J Cardiol 2000; 86: 353-357 GISSI-3: Six-month data. J Am Coll Cardiol 1996; 27: 337-344 Tavazzi L et al. The Italian survey on Acute Heart Failure. Eur Heart J 2006; 27: 1207-1215

  20. Research in acute HF: Conclusions • Morbidity and mortality of patients with acute HF remain unacceptably high • Treatment of acute HF continues to remain largely anecdotal without much progress in the last decades • Risk stratification with the identification of simple clinical variables seems to be feasible in any clinical setting • In any case, the application of risk scores in the real world of acute HF could be limited by: • The heterogeneity of this clinical condition • The different patho-physiological background • The various clinical settings (and doctor profiles) in which patients with AHF are managed • Further efforts should be focused on planning research in the field of AHF

  21. Data on the clinical characteristics. Definition, sub-clasification (ST/non-ST ) Data on the exact pathophysiology of each subtype. Better ways to risk-stratify the patients. Treatments to: Reduce Mortality Reduce Morbidity (worsening heart failure?) Rapid and safe symptoms relief Or in other words … everything… What do we need ?

  22. Comparisonofdecompensatedheartfailurewith acute myocardialinfarction Decompensated Acute myocardial Heart failure infarction Hospitalization per year(in US)  1,000,000  1,000,000 In-Hospital Mortality 3-12% 3-7% Readmission rate (60 days) 35% 10% Guidelines for risk stratification No Yes Guidelines for therapy Yes (ESC) Yes No (AHA/ACC) Largest randomized trial 4,133 41,021 MEDLINE citations (1965-2006) 472 33,908 Modified from Am Heart J 2003; 145: S18-25

More Related